See the published version of this preprint at BMC Psychiatry.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Bo Zhou
Sichuan Academy of Medical Sciences and Sichuan People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4691-2801
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: A number of studies have shown that genetic factor plays an important
role in etiology of panic disorder (PD). The aim of the present study was to examine the association of serotonin-related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug.
Methods: 233 patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4 weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), 5-HTR1A rs6295, 5-HTR2A rs6313 and COMT rs4680 gene polymorphisms were genotyped and assessed for the potential association.
Results: The allelic model showed that the SLC6A4 rs140701 polymorphism variant was significantly associated with increased risk of PD (OR = 0.624, 95 % CI 0.450-0.864, p<0.05), and a significant result was found in the dominant model (OR = 0.546; 95% CI, 0.371-0.804, p<0.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR = 0.205, 95 % CI 0.128-0.328; OR = 0.249, 95 % CI 0.155-0.401, both p <0.001), indicating the PD patients with S-allele had a poorer response to sertraline than L-allele carriers.
Conclusions: The present study suggests that the SLC6A4 rs140701 polymorphism variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertraline in the treatment of PD.
Keywords
Panic disorder, Serotonin transporter, Polymorphism, Setraline
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Psychiatry.
No community comments so far
Submission checks complete
On 20 Jul, 2020
Editorial decision: Accept
On 20 Jul, 2020
Version 2
Posted 12 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 16 Jul, 2020
Review #2 received
Received 02 Jul, 2020
Review #1 received
Received 17 Jun, 2020
Reviewer #2 agreed
On 13 Jun, 2020
Reviewer #1 agreed
On 12 Jun, 2020
Reviewers invited
Invitations sent on 09 Jun, 2020
Editor assigned
On 08 Jun, 2020
Submission checks complete
On 07 Jun, 2020
Editor invited
On 07 Jun, 2020
No comments provided
Editorial decision: Major revision
On 18 May, 2020
Review #3 received
Received 17 May, 2020
Reviewer #3 agreed
On 22 Apr, 2020
Review #1 received
Received 13 Apr, 2020
Review #2 received
Received 31 Mar, 2020
Reviewer #2 agreed
On 26 Mar, 2020
Reviewers invited
Invitations sent on 10 Mar, 2020
Reviewer #1 agreed
On 10 Mar, 2020
First submitted
On 27 Feb, 2020
Editor assigned
On 27 Feb, 2020
Submission checks complete
On 26 Feb, 2020
Editor invited
On 26 Feb, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Psychiatry
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Psychiatry.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Bo Zhou
Sichuan Academy of Medical Sciences and Sichuan People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4691-2801
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Psychiatry.
No community comments so far
Submission checks complete
On 20 Jul, 2020
Editorial decision: Accept
On 20 Jul, 2020
Version 2
Posted 12 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 16 Jul, 2020
Review #2 received
Received 02 Jul, 2020
Review #1 received
Received 17 Jun, 2020
Reviewer #2 agreed
On 13 Jun, 2020
Reviewer #1 agreed
On 12 Jun, 2020
Reviewers invited
Invitations sent on 09 Jun, 2020
Editor assigned
On 08 Jun, 2020
Submission checks complete
On 07 Jun, 2020
Editor invited
On 07 Jun, 2020
No comments provided
Editorial decision: Major revision
On 18 May, 2020
Review #3 received
Received 17 May, 2020
Reviewer #3 agreed
On 22 Apr, 2020
Review #1 received
Received 13 Apr, 2020
Review #2 received
Received 31 Mar, 2020
Reviewer #2 agreed
On 26 Mar, 2020
Reviewers invited
Invitations sent on 10 Mar, 2020
Reviewer #1 agreed
On 10 Mar, 2020
First submitted
On 27 Feb, 2020
Editor assigned
On 27 Feb, 2020
Submission checks complete
On 26 Feb, 2020
Editor invited
On 26 Feb, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Psychiatry
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Psychiatry.
Background: A number of studies have shown that genetic factor plays an important
role in etiology of panic disorder (PD). The aim of the present study was to examine the association of serotonin-related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug.
Methods: 233 patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4 weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), 5-HTR1A rs6295, 5-HTR2A rs6313 and COMT rs4680 gene polymorphisms were genotyped and assessed for the potential association.
Results: The allelic model showed that the SLC6A4 rs140701 polymorphism variant was significantly associated with increased risk of PD (OR = 0.624, 95 % CI 0.450-0.864, p<0.05), and a significant result was found in the dominant model (OR = 0.546; 95% CI, 0.371-0.804, p<0.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR = 0.205, 95 % CI 0.128-0.328; OR = 0.249, 95 % CI 0.155-0.401, both p <0.001), indicating the PD patients with S-allele had a poorer response to sertraline than L-allele carriers.
Conclusions: The present study suggests that the SLC6A4 rs140701 polymorphism variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertraline in the treatment of PD.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...